Given anti-CTLA-4 as a well-established ICB therapy, these findings raise a possibility of DCs mediating anti-CTLA-4 effects in vivo and validate the targeting of CTLA-4 on DCs to enhance ICB efficacy-in cancers. This evidence concerns the gene CTLA4 and cancer.